中国医药(600056.SH)子公司获瑞舒伐他汀依折麦布片(I)药品注册批件

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has received the drug registration certificate for Rosuvastatin Ezetimibe Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating high cholesterol levels and familial hypercholesterolemia [1] Group 1 - The approved drug, Rosuvastatin Ezetimibe Tablets, is primarily used for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) [1] - The combination of Ezetimibe and Rosuvastatin calcium is expected to enhance lipid-lowering efficacy and reduce cardiovascular events [1]